GINA Genetic Privacy Protections in Health Insurance
Author: HHS Press Office
Published: 2009/10/02 - Updated: 2026/02/11
Publication Type: Announcement
Category Topic: Laws and Rights - Related Publications
Contents: Synopsis - Introduction - Main - Insights, Updates
Synopsis: This announcement from the U.S. Department of Health and Human Services details federal protections established under the Genetic Information Nondiscrimination Act of 2008 (GINA) that prevent health insurance companies from misusing genetic testing data. The information holds particular value for people with disabilities, seniors, and individuals considering genetic testing who need assurance that their test results cannot be weaponized against them in the insurance marketplace. By establishing clear prohibitions on premium increases, coverage denials, and pre-existing condition exclusions based on genetic data, these regulations remove a significant barrier that previously discouraged many Americans from pursuing genetic testing that could lead to early disease detection and more effective treatment strategies - Disabled World (DW).
- Topic Definition: Genetic Information Nondiscrimination Act (GINA)
The Genetic Information Nondiscrimination Act, passed in 2008, prohibits health insurers and employers from discriminating against people based on their genetic information. Under GINA, health insurance companies can't use your genetic test results - or those of your family members - to deny coverage, adjust your premiums, or treat you differently when making decisions about your eligibility. Similarly, employers are barred from using genetic information in hiring, firing, promotion, or any other employment decisions, and they can't even request or require genetic testing as a condition of employment. The law defines genetic information broadly to include not just DNA test results but also family medical history and participation in genetic research. While GINA offers important protections, it has notable gaps: it doesn't apply to life insurance, disability insurance, or long-term care insurance, and it doesn't cover employers with fewer than fifteen employees. The legislation was a response to growing concerns that advances in genetic testing could lead to a new form of discrimination, potentially discouraging people from pursuing beneficial genetic screening out of fear their results could be used against them.
Introduction
Laws To Protect Patients Genetic Information
The interim final rule will help ensure that genetic information is not used adversely in determining health care coverage and will encourage more individuals to participate in genetic testing, which can help better identify and prevent certain illnesses.
"Echoing the late Senator Ted Kennedy, our efforts to protect Americans undergoing genetic testing from having the results of that testing used against them by their insurance companies is one of the 'first major new civil rights' of the new century," said HHS Secretary Kathleen Sebelius. "Consumer confidence in genetic testing can now grow and help researchers get a better handle on the genetic basis of diseases. Genetic testing will encourage the early diagnosis and treatment of certain diseases while allowing scientists to develop new medicines, treatments, and therapies."
Main Content
The interim final rule with request for comments and the notice of proposed rule-making implement Title I of the Genetic Information Nondiscrimination Act of 2008 (GINA). Under GINA, and the interim final rule, group health plans and issuers in the group market cannot: increase premiums for the group based on the results of one enrollee's genetic information; deny enrollment; impose pre-existing condition exclusions; or do other forms of underwriting based on genetic information.
In the individual health insurance market, GINA prohibits issuers from using genetic information to deny coverage, raise premiums, or impose pre-existing condition exclusions.
Further, under GINA and the new interim final regulations, group health plans and health insurance issuers in both the group and individual markets cannot request, require or buy genetic information for underwriting purposes or prior to and in connection with enrollment. Finally, plans and issuers are generally prohibited from asking individuals or family members to undergo a genetic test.
"Genetic technologies yield data that are vital to helping Americans make personal, medical decisions. It is essential that we protect such information and ensure it is not misused by health plans or insurers," said Labor Secretary Hilda L. Solis. "The rules issued protect individuals against the unwarranted use of information related to their personal health because no one should have to fear that disclosure of their medical data will put their job or health coverage at risk."
Additionally, HHS, through its Office for Civil Rights (OCR), issued a notice of proposed rule-making with a 60-day comment period, to propose changes to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule to prohibit health plans from using or disclosing genetic information for underwriting purposes.
The proposed rule modifies the HIPAA Privacy Rule pursuant to GINA Title I to clarify that genetic information is health information and to prohibit the use and disclosure of genetic information by covered health plans for eligibility determinations, premium computations, applications of any pre-existing condition exclusions, and any other activities related to the creation, renewal, or replacement of a contract of health insurance or health benefits.
In combination with the new penalties for violations of the HIPAA Privacy Rule, as provided for by the American Recovery and Reinvestment Act of 2009, a use or disclosure of genetic information in violation of the HIPAA Privacy Rule could result in a fine of $100 to $50,000 or more for each violation.
Insights, Analysis, and Developments
Editorial Note: The implementation of GINA's Title I regulations represents a turning point in medical privacy law, directly addressing the conflict between advancing genetic science and protecting individual rights. While these protections have stood for over a decade, their relevance has only intensified as genetic testing becomes more accessible and affordable through direct-to-consumer services and routine medical care. The framework these regulations establish - prohibiting insurers from even requesting genetic information for underwriting purposes - creates the trust necessary for patients to make informed medical decisions without economic coercion. For the disability community especially, where genetic conditions often intersect with insurance needs, these protections serve as both shield and enabler, allowing individuals to pursue potentially life-changing medical insights while maintaining their access to essential health coverage - Disabled World (DW).Attribution/Source(s): This quality-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by HHS Press Office and published on 2009/10/02, this content may have been edited for style, clarity, or brevity.